Trials in AF and acute coronary syndrome were stopped early for futility, but there’s hope for factor XIa inhibitors given ...

Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...

Remote screening with a smartwatch detected new-onset atrial fibrillation more often vs. standard care among patients at ...

High discontinuation rates of OACs in NVAF patients, with 47% stopping within 120 days, highlight adherence challenges. DOACs show a lower risk of discontinuation compared to warfarin, suggesting ...

Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial. The trial had been stopped early because of a surprisingly large reduction in bleeds ...

Anticoagulant therapy for ischaemic stroke aims to prevent recurrent ischaemic stroke and venous thromboembolism. Several large clinical trials have provided insight into the safety and efficacy of ...

The Global Peptide and Anticoagulant Drugs Market is experiencing robust growth, driven by the increasing prevalence of cardiovascular diseases, technological advancements, and the emergence of new ...

Formulary restrictions can create treatment barriers for patients with atrial fibrillation, including unnecessary delays in treatment and prescription abandonment, with vulnerable populations at ...

Please provide your email address to receive an email when new articles are posted on . Since 2010, the FDA has approved four direct oral anticoagulants as alternatives to warfarin: dabigatran ...

Background: Patients taking oral anticoagulant therapy balance the risks of hemorrhage and thromboembolism. We sought to determine the association between anticoagulation intensity and the risk of ...

New research presented at ACR Convergence, the American College of Rheumatology's annual meeting, shows that use of warfarin, a vitamin K drug widely prescribed to prevent blood clots, is associated ...

Clotting problems and resulting complications are common in COVID-19 patients. Researchers have now shown that a member of the anticoagulant group of drugs not only has a beneficial effect on survival ...